The antibodies market size in the Asia Pacific was valued at USD 14.23 Billion in 2023. This value is estimated to reach USD 22.78 Billion by the end of 2028, showcasing a growing potential of 9.87% CAGR during the forecast period.
The APAC region has the fastest growth rate of the antibodies market in the world. The chronic disease burden of the region is increasing; thus, there is a rise in the research on monoclonal antibodies. The technological advancements and progressive R&D in antibodies in Asia Pacific countries like India, China, Japan, and Australia are expected to propel market growth. Antibodies are used in research to develop new diagnoses and treatments for rare diseases and to study different biomarkers of different conditions. There is significant adoption of therapeutic antibodies in this region, and the regulatory bodies in the area also have approved the treatment at a fast track without affecting safety. There are many antibody products in the clinical trials in the region, and research has been going on in this region to create a vaccine for COVID-19 by using the antibody resistance to coronavirus.
The cost of antibody treatment is high, and the process is complex, restraining the Asia Pacific market growth to some extent. In addition, some side effects of the antibody’s treatment include an allergic reaction, flu-like symptoms, vomiting, diarrhea, and low blood pressure, which are predicted to impact the market to a limited extent negatively. In addition, less awareness in undeveloped countries further degrades market growth.
This research report on the APAC antibodies market has been segmented and sub-segmented into the following categories:
By Product Type:
Based on product type, the monoclonal antibodies held the major share of the APAC antibodies market in 2022.
Based on indication, the cancer segment is anticipated to lead the market during the forecast period.
By End User:
Regionally, APAC occupied a considerable share of the worldwide market in 2022 and is forecasted to grow at the highest CAGR among all the regions during the forecast period.
The Indian antibodies market is one of the potential markets for antibodies in the Asia-pacific region. It is anticipated to grow at the highest CAGR during the forecast period. The National Institute of Immunology (NII) has generated monoclonal antibodies to detect typhoid fever and the hepatitis B virus. In addition, NII is also developing monoclonal antibodies against rotavirus and virulent strains of E. coli.
The Chinese antibodies market held the major share of the APAC market in 2021, and the domination of the Chinese market in the APAC region is expected to continue in the coming years. China has many institutes that are researching antibodies. In addition, China is trying to develop a vaccine for COVID-19.
During the forecast period, the Japanese market is expected to capture a substantial share of the APAC market and witness a healthy CAGR. The Japanese government is promoting the production of biosimilars using antibodies. Japan has also developed antibodies for anti-glycosaminoglycan.
KEY MARKET PLAYERS:
Companies that play a promising role in the APAC antibodies market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc, ThermoFisher Scientific Inc, Eli Lilly and Company, A.G. Scientific, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.
The antibodies market in APAC is estimated to grow at a CAGR of 9.87% from 2023 to 2028.
Factors such as the increasing prevalence of chronic diseases, rising demand for personalized medicine, growing investments in research and development, and technological advancements in the development of monoclonal antibodies are propelling the antibodies market growth in the Asia-Pacific region.
China held the major share of the APAC antibodies market in 2022.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org